Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Alternative Names: huPMN310; PMN 300; PMN 320; PMN 330; PMN 340; PMN 350; PMN-310; TDP 43 targeting therapeutics

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Superoxide dismutase inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Parkinson's disease

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia
  • Research Down syndrome; Lewy body disease; Parkinson's disease

Most Recent Events

  • 03 Jul 2018 Preclinical development is ongoing in Amyotrophic-lateral-sclerosis in Canada (Parenteral) (ProMIS Neurosciences Pipeline; 9244075)
  • 26 Jun 2018 Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences is available for licensing as of 26 Jun 2018. https://promisneurosciences.com/
  • 12 Jun 2018 ProMIS Neurosciences plans a phase I trial of PMN 310 for Alzheimer's disease, in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top